VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $24.06M
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 39,620,316
• 10 Day Avg. Volume: 1,055,596
• 30 Day Avg. Volume: 1,225,812
• PEG Ratio: -0.15
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 157.98
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: -1.05
• Enterprise Value/Revenue: -32.01
• Enterprise Value/Gross Profit: -58.54
• Enterprise Value/Ebitda: 0.37
• 1Y Price Target: $1.00
• Price Target Upside: 63.93% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.77
• Revenue Forecast (FY): $1.05M

• Rating: 45 Neutral
• Price Target: $0.61 ▲(0.66% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by sustained large losses and heavy cash burn on minimal revenue, combined with a weak long-term price trend and negative MACD. Neutral-to-mixed clinical/program updates and low leverage provide some support, but are outweighed by delisting risk and the PALISADE-3 setback.

Positive Factors

Differentiated nose-to-brain platform

VistaGen’s intranasal pherine platform targets nasal chemosensory neurons for localized, rapid neurocircuit modulation and supports multiple clinical-stage programs. This technology and multi-indication pipeline create durable optionality for partnerships and non-dilutive exits across CNS disorders.

Progress in pivotal program execution

Completion of PALISADE-3 randomized dosing and ongoing PALISADE-4 enrollment preserve the integrity of the pivotal program timeline. Sustained execution reduces program risk versus early-stage peers and keeps potential NDA-enabling data within a multi-quarter horizon.

Cash on hand and cost controls

A $61.8M cash balance coupled with active cost-saving measures and a workforce reduction extends near-term runway. This enhances the company’s ability to fund PALISADE-4 completion and planned IND activities without immediate dilutive financing if execution stays on plan.

Negative Factors

Sustained high cash burn

Persistent ~-$60M annual cash burn ties corporate viability to future financings or near-term pipeline milestones. Even with cost cuts, such negative cash flow pressures strategic options, increases fundraising frequency, and risks dilution if pivotal results or partnerships do not materialize.

PALISADE-3 primary endpoint failure

A failed Phase 3 primary endpoint is a durable structural setback: it raises efficacy uncertainty across the program, complicates regulatory strategy, increases need for additional trials/analyses, and weakens bargaining power with partners or acquirers over the medium term.

Nasdaq minimum bid non-compliance

Nasdaq non-compliance introduces delisting risk and forces management to prioritize share-price remediation activities (e.g., financings, reverse splits) that can distract from operations. The listing pressure also narrows financing windows and may raise long-term investor confidence hurdles.

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

How the Company Makes Money

VistaGen is a clinical-stage company and, as of the latest publicly available information within this response, it does not have established recurring revenue from product sales. Its operations have historically been funded primarily through financing activities such as issuing equity (e.g., public offerings/ATM programs) and, where applicable, proceeds from collaborations, licensing, or other strategic transactions. Specific, material details on current recurring revenue streams, product-level commercial revenues, or active partnership economics (e.g., milestone/royalty structures) are not reliably available here; therefore, any such details are null.

VistaGen Therapeutics Financial Statement Overview

Summary

Overall fundamentals are weak: revenue remains very small (~$0.8M TTM) with large net losses (~-$67.0M) and substantial ongoing cash burn (operating/FCF about -$60M TTM). The main offset is low leverage (debt-to-equity ~0.02), but the business remains financing-dependent.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (~$0.8M) despite modest growth (+9.6%), and profitability is deeply negative (net loss of ~$67.0M with sharply negative margins). Gross margin is positive (~40% in TTM), but operating costs dominate and losses have widened versus the prior annual periods, indicating limited scale and weak operating leverage.

Balance Sheet

Leverage is low (debt-to-equity ~0.02 in both TTM and the latest annual period), which reduces balance sheet risk. However, equity has declined meaningfully over time and returns on equity are very negative (TTM ROE about -1.10), reflecting ongoing heavy losses and continued pressure on the capital base if losses persist.

Cash Flow

Cash burn remains substantial with negative operating cash flow (~-$60.3M TTM) and negative free cash flow (~-$60.4M TTM). Free cash flow has improved versus the prior annual period (positive growth in TTM), but cash generation is still firmly negative, and cash outflows broadly track net losses, highlighting continued funding dependence.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	790.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
Gross Profit	432.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
EBITDA	-67.84M	-55.34M	-32.45M	-58.74M	-47.05M	-17.44M
Net Income	-67.05M	-51.42M	-29.36M	-59.25M	-47.76M	-17.93M
Balance Sheet
Total Assets	65.06M	84.34M	123.65M	21.09M	74.64M	108.28M
Cash, Cash Equivalents and Short-Term Investments	61.77M	80.48M	119.17M	16.64M	68.14M	103.11M
Total Debt	1.43M	1.51M	2.12M	2.71M	3.04M	3.72M
Total Liabilities	14.14M	13.95M	9.37M	9.01M	9.93M	16.30M
Stockholders Equity	50.92M	70.39M	114.29M	12.08M	64.72M	91.98M
Cash Flow
Free Cash Flow	-60.39M	-42.29M	-25.87M	-49.93M	-45.46M	-12.35M
Operating Cash Flow	-60.30M	-42.10M	-25.81M	-49.72M	-45.26M	-12.07M
Investing Cash Flow	-251.00K	-13.15M	-61.00K	-740.00K	-200.40K	-275.40K
Financing Cash Flow	33.20M	3.21M	128.40M	-1.04M	10.48M	114.10M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.61
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Neutral. The current price of 0.61 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.61, and below the 200-day MA of 2.52, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 44.80 is Neutral, neither overbought nor oversold. The STOCH value of 58.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IKT	54 Neutral	$242.53M	-3.06	-131.71%	―	-100.00%	79.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$216.09M	-0.39	―	―	-63.96%	-28.50%
SPRO	48 Neutral	$145.36M	-3.58	-125.91%	―	-67.38%	-1076.54%
OVID	47 Neutral	$256.46M	-1.90	-63.74%	―	946.61%	-11.30%
VTGN	45 Neutral	$24.06M	-0.37	―	―	-33.00%	54.91%
MGNX	43 Neutral	$190.67M	-1.36	-81.13%	―	-9.70%	23.23%

VistaGen Therapeutics Corporate Events

VistaGen Showcases Intranasal Pherine Pipeline in New Presentation

On March 16, 2026, VistaGen Therapeutics began using a new corporate presentation outlining its strategy to pioneer nose-to-brain neurocircuit modulation with non-systemic intranasal pherines. The deck highlights five clinical-stage candidates, favorable safety data to date and significant U.S. market potential, including positive Phase 2 and Phase 3 results for fasedienol in social anxiety disorder, underscoring VistaGen’s bid to strengthen its positioning in high-need CNS indications and attract potential partners and capital.

The presentation emphasizes that pherines are synthetic, steroid-like molecules acting on nasal chemosensory neurons to rapidly influence neurocircuits linked to emotion, stress, autonomic function and metabolism, with no detectable brain uptake or systemic exposure. By detailing distinct mechanisms across programs in major depressive disorder, menopausal hot flashes, premenstrual dysphoric disorder, psychomotor and cognitive impairment, and cancer cachexia, VistaGen signals an effort to broaden its therapeutic footprint and create multiple value-creation pathways for stakeholders as development advances.

The most recent analyst rating on (VTGN) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen Announces Workforce Reduction to Extend Cash Runway

On March 5, 2026, Vistagen Therapeutics, Inc. implemented a Board-approved workforce reduction of approximately 20% to tighten cash management while maintaining efficient execution of its PALISADE clinical program for fasedienol in social anxiety disorder. Affected employees may receive cash severance and temporary healthcare coverage if they sign separation agreements that include a general release of claims, with the company expecting related costs to be immaterial.

Vistagen indicated it expects topline results from its PALISADE-4 Phase 3 trial of fasedienol in the first half of 2026 and projects its cash runway to extend into 2027, underscoring its focus on preserving capital for late-stage clinical milestones. The move signals a shift toward operational efficiency as the company navigates pivotal trial readouts, with potential implications for its positioning in the CNS therapeutics space and for stakeholders monitoring its liquidity and development timelines.

The most recent analyst rating on (VTGN) stock is a Hold with a $0.60 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen Receives Nasdaq Notice on Minimum Bid Compliance

On February 3, 2026, Vistagen Therapeutics, Inc. received a notice from Nasdaq that the company’s common stock had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing standards. While the letter has no immediate impact on the stock’s current listing, Vistagen now has until August 3, 2026 to restore its share price to at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day compliance period if it meets other listing criteria, a development that underscores ongoing pressure on the company’s share price and introduces potential delisting risk for investors if compliance is not regained.

The most recent analyst rating on (VTGN) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen updates corporate presentation highlighting neuroscience pipeline

On January 9, 2026, Vistagen Therapeutics began using a new corporate presentation that outlines its vision to pioneer breakthroughs in neuroscience by leveraging nose-to-brain neurocircuitry, highlighting a differentiated platform of intranasal pherine candidates designed for rapid-onset, localized action without systemic absorption or direct brain uptake. The deck underscores favorable safety and tolerability across completed trials, details an advancing clinical pipeline led by fasedienol in an ongoing PALISADE Phase 3 program for acute treatment of social anxiety disorder—supported by positive results from two Phase 2 and one Phase 3 study—as well as other candidates in major depressive disorder, psychomotor/cognitive impairment, menopausal vasomotor symptoms, premenstrual dysphoric disorder, and cancer cachexia, positioning the company to pursue substantial partnering and commercialization opportunities in multiple high-need therapeutic markets.

The most recent analyst rating on (VTGN) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD

On December 17, 2025, Vistagen Therapeutics reported that its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol for the acute treatment of social anxiety disorder failed to meet its primary endpoint, with no meaningful difference observed between fasedienol and placebo on the Subjective Units of Distress Scale, and no treatment difference on secondary endpoints, although the drug continued to show a favorable safety profile consistent with prior studies. The negative Phase 3 outcome represents a significant setback for the company’s lead social anxiety program and may prompt reassessment of its late-stage development strategy and timelines, even as the safety data could preserve some optionality for future clinical or partnering considerations.

The most recent analyst rating on (VTGN) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.